Press Release: Foresight Diagnostics : NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma

BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National Comprehensive Cancer...